scholarly journals Population Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I and II Clinical Trials

2017 ◽  
Vol 57 (8) ◽  
pp. 977-988 ◽  
Author(s):  
Ben Klünder ◽  
Mohamed-Eslam F. Mohamed ◽  
Ahmed A. Othman
Keyword(s):  
Rheumatoid Arthritis ◽  
Clinical Trials ◽  
Phase I ◽  
Population Pharmacokinetics ◽  
Healthy Subjects ◽  
Phase I And Ii

scholarly journals Osteosarcoma Pathogenesis Leads the Way to New Target Treatments

2021 ◽  
Vol 22 (2) ◽  
pp. 813
Author(s):  
Isabel Fernandes ◽  
Cecília Melo-Alvim ◽  
Raquel Lopes-Brás ◽  
Miguel Esperança-Martins ◽  
Luís Costa
Keyword(s):  
Clinical Trials ◽  
Phase I ◽  
Poor Prognosis ◽  
Therapeutic Targets ◽  
Rare Condition ◽  
Basic Research ◽  
Metastatic Setting ◽  
Phase I And Ii ◽  
The Way

Osteosarcoma (OS) is a rare condition with very poor prognosis in a metastatic setting. Basic research has enabled a better understanding of OS pathogenesis and the discovery of new potential therapeutic targets. Phase I and II clinical trials are already ongoing, with some promising results for these patients. This article reviews OS pathogenesis and new potential therapeutic targets.

Toxicity profiles of HER2/neupeptide anticancer vaccines: the picture from Phase/I and II clinical trials

2012 ◽  
Vol 11 (6) ◽  
pp. 637-640 ◽  
Author(s):  
Constantin N Baxevanis ◽  
Michael Papamichail ◽  
Sonia A Perez
Keyword(s):  
Clinical Trials ◽  
Phase I ◽  
Anticancer Vaccines ◽  
Phase I And Ii

scholarly journals Phase I and II clinical trials of trastuzumab

2001 ◽  
Vol 12 ◽  
pp. S49-S55 ◽  
Author(s):  
J. Baselga
Keyword(s):  
Clinical Trials ◽  
Phase I ◽  
Phase I And Ii

Investigational treatments in phase I and II clinical trials: a systematic review in chronic obstructive pulmonary disease (COPD)

2020 ◽  
Vol 29 (7) ◽  
pp. 723-738
Author(s):  
Luigino Calzetta ◽  
Beatrice Ludovica Ritondo ◽  
Maria Gabriella Matera ◽  
Gabriella Pezzuto ◽  
Mario Cazzola ◽  
...  
Keyword(s):  
Systematic Review ◽  
Chronic Obstructive Pulmonary Disease ◽  
Clinical Trials ◽  
Phase I ◽  
Pulmonary Disease ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Phase I And Ii

Tolerability of pemetrexed and oxaliplatin in the treatment of stage III colon cancer during raltitrexed shortage

2020 ◽  
pp. 107815522093416
Author(s):  
Jasmine Giani ◽  
Michael B Sawyer ◽  
Carole Chambers
Keyword(s):  
Colorectal Cancer ◽  
Colon Cancer ◽  
Clinical Trials ◽  
Case Report ◽  
Adverse Events ◽  
Phase I ◽  
Stage Iii ◽  
Stage Iii Colon Cancer ◽  
Colorectal Cancer Treatment ◽  
Phase I And Ii

Colorectal cancer is one of the most common malignancies diagnosed in Canada. Currently, adjuvant colorectal cancer treatment primarily includes chemotherapeutic regimens such as FOLFOX6 (5-fluorouracil, leucovorin, oxaliplatin) or CAPOX (capecitabine, oxaliplatin), as well as alternative regimens such as TOMOX (raltitrexed, oxaliplatin). However, the prevalence of drug shortages in today’s society may make these preferred regimens inaccessible. The purpose of this case report is to highlight the tolerability of an alternative adjuvant regimen (pemetrexed plus oxaliplatin) that has undergone both phase I and II clinical trials for the treatment of colorectal cancer. The patient presented in this case report is a 57-year-old female diagnosed with Stage III colon cancer. This patient received seven cycles of pemetrexed plus oxaliplatin and experienced several adverse events, with the majority of them being mild in nature including fatigue and cold dysesthesia. However, the patient also experienced progressive neuropathy which required a dose reduction and subsequent discontinuation of oxaliplatin. Overall, pemetrexed and oxaliplatin’s tolerability seems comparable to other regimens used to treat colorectal cancer and could potentially be an option to consider in the future for alternative treatment of colorectal cancer pending further trials.

Sign in / Sign up

Export Citation Format

Share Document